文献速递头颈部肿瘤放疗放疗物理与技术

自适应FDG-PET/CT引导剂量递增治疗头颈部鳞状细胞癌:晚期毒性与肿瘤学结局(ADMIRE研究)

Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study).
PubMed 文献 · Clin Transl Radiat Oncol · 2023-09-17

ADMIRE研究纳入20例II-IV期喉、下咽或口咽鳞癌患者,采用FDG-PET/CT反应引导(第2和4周)剂量递增放疗(总剂量70-78 Gy),并与同期67例接受70 Gy标准放疗的合格未入组患者进行外部对照比较。中位随访40和43个月后,3年局部控制率分别为74%和78%(校正HR 0.80,95%CI 0.25-2.52,p=0.70),但ADMIRE组晚期G3毒性发生率更高(35% vs 18%),多项晚期毒性校正OR显著升高。作者认为,鉴于局部控制率相当而晚期毒性增加,未来自适应剂量递增试验的选择标准需细化。

要点

  • ADMIRE组3年局部控制率74%,对照组78%,校正后无显著差异(HR 0.80,95%CI 0.25-2.52,p=0.70)。
  • ADMIRE组任何晚期G3毒性发生率为35%,对照组为18%,校正OR 5.09(95%CI 1.64-15.8,p=0.005)。
  • ADMIRE组持续性喉水肿、持续性黏膜溃疡、晚期G3放射性坏死的校正OR分别为10.95、4.67、15.69。

核心结论

  • ADMIRE组与对照组局部控制率相当,但ADMIRE组晚期毒性增加;未来自适应剂量递增试验的选择标准需细化,仅纳入局部失败风险更高和/或严重晚期毒性风险更低的患者。

研究设计与样本

  • ADMIRE研究为前瞻性研究(NCT03376386),2017年12月至2019年4月纳入20例II-IV期喉、下咽或口咽鳞状细胞癌患者,接受FDG-PET/CT反应引导(第2和4周)剂量递增放疗(总剂量70-78 Gy);T3-4和/或N2c疾病患者联合顺铂或西妥昔单抗。
  • 外部对照组(n=67)由同期本机构收治的所有符合研究条件但未参与研究的患者组成,接受当前标准70 Gy放疗。
  • 采用稳定化逆概率治疗加权(SIPTW)后的逻辑回归分析以减少混杂效应。

主要发现

  • ADMIRE组和对照组中位随访分别为40个月和43个月,3年局部控制率分别为74%和78%(SIPTW校正HR 0.80,95%CI 0.25-2.52,p=0.70)。
  • ADMIRE组任何晚期G3毒性发生率为35%,对照组为18%;校正OR为5.09(95%CI 1.64-15.8,p=0.005)。
  • ADMIRE组任何晚期G≥2毒性校正OR为3.67(95%CI 1.2-11.7,p=0.02)。
  • ADMIRE组持续性喉水肿校正OR为10.95(95%CI 2.71-44.29,p=0.001),持续性黏膜溃疡校正OR为4.67(95%CI 1.23-17.7,p=0.023),晚期G3放射性坏死校正OR为15.69(95%CI 2.43-101.39,p=0.004)。

临床怎么用

  • 作者认为,鉴于局部控制率相当而晚期毒性增加,未来自适应剂量递增试验的选择标准需细化,仅纳入局部失败风险更高和/或严重晚期毒性风险更低的患者,并优选随机化设计。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report on the late toxicity and local control (LC) of head and neck cancer patients treated with adaptive FDG-PET/CT response-guided radiotherapy (ADMIRE) with dose escalation (NCT03376386). MATERIALS AND METHODS: Between December 2017 and April 2019, 20 patients with stage II-IV squamous cell carcinoma of the larynx, hypopharynx or oropharynx were treated within the ADMIRE study where FDG-PET/CT response-guided (Week 2&4) dose escalation was applied (total dose 70-78 Gy). Cisplatin or cetuximab was added to radiotherapy in case of T3-4 and/or N2c disease. To compare the LC and late toxicity of the study population, we used an external control group (n = 67) consisting of all eligible patients for the study (but not participated). These patients were treated in our institution during the same period with the current standard of 70 Gy radiotherapy. To reduce the effect of confounding, logistic regression analyses was done using stabilized inverse probability of treatment weighting (SIPTW). RESULTS: After median follow-up of 40 and 43 months for the ADMIRE and control groups, the 3-year LC-rates were 74% and 78%, respectively (adjusted HR after SIPTW 0.80, 95 %CI 0.25-2.52, p = 0.70). The incidences of any late G3 toxicity were 35% and 18%, respectively. The adjusted OR for any late G3 toxicity was 5.09 (95 %CI 1.64-15.8, p = 0.005), for any late G ≥ 2 toxicity was 3.67 (95 %CI 1.2-11.7, p = 0.02), for persistent laryngeal edema was 10.95 (95% CI 2.71-44.29, p = 0.001), for persistent mucosal ulcers was 4.67 (95% CI 1.23-17.7, p = 0.023), and for late G3 radionecrosis was 15.69 (95 %CI 2.43-101.39, p = 0.004). CONCLUSION: Given the comparable LC rates with increased late toxicity in the ADMIRE group, selection criteria for future adaptive dose escalation trials (preferably randomized) need to be refined to include only patients at higher risk of local failure and/or lower risk of severe late toxicity.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Al-Mamgani A, Kessels R, Gouw ZAR, et al. Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study). Clin Transl Radiat Oncol. 2023. PMID: 37753461. doi:10.1016/j.ctro.2023.100676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。